Stockscreener 앱 받기
2.985
0.50%
-0.015
시간 외 거래:
2.97
-0.015
-0.50%
전일 마감가:
$3.00
열려 있는:
$3
하루 거래량:
5,072
Relative Volume:
0.11
시가총액:
$252.83M
수익:
-
순이익/손실:
$-29.64M
주가수익비율:
-6.9419
EPS:
-0.43
순현금흐름:
$-39.43M
1주 성능:
-0.50%
1개월 성능:
+10.15%
6개월 성능:
+6.61%
1년 성능:
+19.40%
1일 변동 폭
$2.92
$3.0365
1주일 범위
$2.92
$3.1199
52주 변동 폭
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
DRTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.985 | 254.10M | 0 | -29.64M | -39.43M | -0.43 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-04-24 | 개시 | H.C. Wainwright | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 개시 | Piper Sandler | Overweight |
| 2022-04-04 | 개시 | Citigroup | Buy |
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
Alpha Tau Medical to Present at Jefferies Healthcare Conference - TipRanks
Alpha Tau to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Alpha Tau Medical Ltd. CFO Raphi Levy to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
Alpha Tau Medical Reports Promising Q1 2025 Results - TipRanks
What is HC Wainwright’s Estimate for DRTS Q1 Earnings? - Defense World
Head to Head Review: Alpha Tau Medical (NASDAQ:DRTS) & DarioHealth (NASDAQ:DRIO) - Defense World
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish - MSN
Alpha Tau (DRTS) Advances Cancer Treatment Trials and Expansion Plans | DRTS Stock News - GuruFocus
Alpha Tau Medical Reports Q1 2025 Results and Major Clinical Advances - TipRanks
Alpha Tau reports Q1 EPS (12c), consensus (13c) - TipRanks
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau Medical (DRTS) Projected to Post Earnings on Monday - Defense World
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 0.4% – Should You Sell? - Defense World
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Alpha Tau Medical sets annual meeting for June 17 By Investing.com - Investing.com Nigeria
Alpha Tau Medical Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Alpha Tau Medical sets annual meeting for June 17 - Investing.com
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Appoints Nadav Kidron to Board Following Strategic Investment - TipRanks
Alpha Tau Medical appoints new board member - Investing.com Australia
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention - Yahoo
Renaissance Technologies LLC Has $127,000 Position in Alpha Tau Medical Ltd. (NASDAQ:DRTS) - Defense World
Femasys (NASDAQ:FEMY) & Alpha Tau Medical (NASDAQ:DRTS) Critical Comparison - Defense World
Alpha Tau Medical Announces Participation in May 2025 Investor Conferences - TipRanks
Alpha Tau to Participate in May Investor Conferences - GlobeNewswire
Alpha Tau Reveals Next-Gen Cancer Treatment Updates: CFO Set for Two Exclusive Investor Events - Stock Titan
Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Lifts Earnings Estimates for Alpha Tau Medical - Defense World
Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering - Latham & Watkins LLP
Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating - TipRanks
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Medical (DRTS) Secures $36.9M in Strategic Stock Sale - GuruFocus
Oramed Invests in Alpha Tau (DRTS) with Strategic Partnership | - GuruFocus
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - marketscreener.com
Alpha Tau enters strategic marketing alliance with Oramed - TipRanks
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - The Manila Times
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau Medical (NASDAQ:DRTSW) Shares Up 2.3% – Still a Buy? - Defense World
Comparing ICU Medical (NASDAQ:ICUI) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical Ltd (DRTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):